Associated Papers
Caveolin and NOS in the Development of Muscular Dystrophy.
Nakashima M et al.
International Journal of Molecular Sciences, 2024
Early proteostasis of caveolins synchronizes trafficking, degradation, and oligomerization to prevent toxic aggregation.
Morales-Paytuví F et al.
The Journal of Cell Biology, 2023
Structural analysis of the P132L disease mutation in caveolin-1 reveals its role in the assembly of oligomeric complexes.
Han B et al.
The Journal of Biological Chemistry, 2023
Functional Properties of Two Distinct PTH1R Mutants Associated With Either Skeletal Defects or Pseudohypoparathyroidism.
Portales-Castillo I et al.
Jbmr Plus, 2022
Molecular architecture of the human caveolin-1 complex.
Porta JC et al.
Science Advances, 2022
Mutational drivers of cancer cell migration and invasion.
Novikov NM et al.
British Journal of Cancer, 2021
A Role for Caveolin-3 in the Pathogenesis of Muscular Dystrophies.
Pradhan BS et al.
International Journal of Molecular Sciences, 2020
Expression of a Human Caveolin-1 Mutation in Mice Drives Inflammatory and Metabolic Defect-Associated Pulmonary Arterial Hypertension.
Rathinasabapathy A et al.
Frontiers in Medicine, 2020
A disease-associated frameshift mutation in caveolin-1 disrupts caveolae formation and function through introduction of a de novo ER retention signal.
Copeland CA et al.
Molecular Biology of the Cell, 2017
Functional polymorphisms of caveolin-1 variants as potential biomarkers of esophageal squamous cell carcinoma.
Wang S et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 2014
Genetic variations of CAV1 gene contribute to HCC risk: a case-control study.
Zhao X et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2014
Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
Choi HJ et al.
Annals of Clinical and Laboratory Science, 2014
Lowered expression levels of a tumor suppressor gene - caveolin-1 within dysregulated gene networks of Fanconi anemia.
Shyamsunder P et al.
Gene, 2013
Overexpression of caveolin-1 is sufficient to phenocopy the behavior of a disease-associated mutant.
Hanson CA et al.
Traffic (copenhagen, Denmark), 2013
Probing the caveolin-1 P132L mutant: critical insights into its oligomeric behavior and structure.
Rieth MD et al.
Biochemistry, 2012
Lack of caveolin-1 (P132L) somatic mutations in breast cancer.
Ferraldeschi R et al.
Breast Cancer Research and Treatment, 2012
Non-existence of caveolin-1 gene mutations in human breast cancer.
Patani N et al.
Breast Cancer Research and Treatment, 2012
5'-CpG island promoter hypermethylation of the CAV-1 gene in breast cancer patients of Kashmir.
Syeed N et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2012
Significant association of caveolin-1 (CAV1) genotypes with breast cancer in Taiwan.
Liu LC et al.
Anticancer Research, 2011
Endolysosomal sorting of ubiquitylated caveolin-1 is regulated by VCP and UBXD1 and impaired by VCP disease mutations.
Ritz D et al.
Nature Cell Biology, 2011
NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.
Wilson KA et al.
Molecular Cancer Research : Mcr, 2011
Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma.
Chen HL et al.
Oncology Reports, 2011
Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced.
Lacroix-Triki M et al.
The Journal of Molecular Diagnostics : Jmd, 2010
Absence of the caveolin-1 P132L mutation in cancers of the breast and other organs.
Koike S et al.
The Journal of Molecular Diagnostics : Jmd, 2010
Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders.
Mercier I et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 2009
Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation.
Mercier I et al.
Cell Cycle (georgetown, Tex.), 2009
Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.
Bonuccelli G et al.
The American Journal of Pathology, 2009
Association of estrogen receptor beta with plasma-membrane caveola components: implication in control of vitamin D receptor.
Gilad LA et al.
Journal of Molecular Endocrinology, 2007
Caveolins bind to (Na+, K+)/H+ exchanger NHE7 by a novel binding module.
Lin PJ et al.
Cellular Signalling, 2007
Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells.
Glait C et al.
Febs Letters, 2006
Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.
Li T et al.
The American Journal of Pathology, 2006
Aberrant dysferlin trafficking in cells lacking caveolin or expressing dystrophy mutants of caveolin-3.
Hernández-Deviez DJ et al.
Human Molecular Genetics, 2006
Cell biology of membrane trafficking in human disease.
Howell GJ et al.
International Review of Cytology, 2006
Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas.
Kakinuma S et al.
Mutation Research, 2005
Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia.
Williams TM et al.
The Journal of Biological Chemistry, 2004
Redefining tumour suppressor genes: exceptions to the two-hit hypothesis.
Paige AJ
Cellular and Molecular Life Sciences : Cmls, 2003
Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice.
Williams TM et al.
Molecular Biology of the Cell, 2003
Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.
Lee H et al.
The American Journal of Pathology, 2002
Invasion activating caveolin-1 mutation in human scirrhous breast cancers.
Hayashi K et al.
Cancer Research, 2001